Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Finished Goods (2024 - 2025)

Syndax Pharmaceuticals has reported Finished Goods over the past 2 years, most recently at $2.2 million for Q3 2025.

  • Quarterly results put Finished Goods at $2.2 million for Q3 2025, changed N/A from a year ago — trailing twelve months through Sep 2025 was $2.2 million (changed N/A YoY), and the annual figure for FY2024 was $36000.0, changed.
  • Finished Goods for Q3 2025 was $2.2 million at Syndax Pharmaceuticals, down from $2.2 million in the prior quarter.
  • Over the last five years, Finished Goods for SNDX hit a ceiling of $2.3 million in Q1 2025 and a floor of $36000.0 in Q4 2024.